Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJMc1509703 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Leveraging mRNA technology for antigen based immuno-oncology therapies.
J Immunother Cancer
January 2025
Moderna, Inc, Cambridge, Massachusetts, USA.
The application of messenger RNA (mRNA) technology in antigen-based immuno-oncology therapies represents a significant advancement in cancer treatment. Cancer vaccines are an effective combinatorial partner to sensitize the host immune system to the tumor and boost the efficacy of immune therapies. Selecting suitable tumor antigens is the key step to devising effective vaccinations and amplifying the immune response.
View Article and Find Full Text PDFSystematic identification of Y-chromosome gene functions in mouse spermatogenesis.
Science
January 2025
Sex Chromosome Biology Laboratory, The Francis Crick Institute, London, UK.
The mammalian Y chromosome is essential for male fertility, but which Y genes regulate spermatogenesis is unresolved. We addressed this by generating 13 Y-deletant mouse models. In , , and deletants, spermatogenesis was impaired.
View Article and Find Full Text PDFAlternative driver pathways in peripheral nerve sheath tumors - including DICER1 and/or KRAS alterations.
J Pathol
January 2025
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
DICER1-associated sarcoma is an emerging entity, defined by either somatic or germline dicer 1, ribonuclease III (DICER1) mutations and sharing characteristic morphologic features irrespective of the site of origin. In addition to the DICER1 driver mutation, concurrent genomic alterations, including tumor protein 53 (TP53) inactivation and RAS pathway activation, are frequently detected. Tumors that morphologically resemble malignant peripheral nerve sheath tumor (MPNST) have rarely been reported among DICER1 sarcomas and often pose diagnostic challenges.
View Article and Find Full Text PDFRethinking cancer evolution: from genetic mutations to complex information systems in tumor reversion.
Evol Med Public Health
December 2024
Department of Surgery, University of Health Sciences, Ankara City Hospital, Cankaya, Ankara, Turkey.
Cancer research has historically focused on the somatic mutation theory, viewing cancer as a consequence of genetic mutations. However, this perspective has limitations in explaining phenomena like tumor reversion and cancer heterogeneity. This paper introduces an alternative approach: viewing cancer as a complex information-processing system shaped by its microenvironment.
View Article and Find Full Text PDFCharacterizing microbial communities and their correlation with genetic mutations in early-stage lung adenocarcinoma: implications for disease progression and therapeutic targets.
Front Oncol
January 2025
Department of Thoracic Surgery, China-Japan Friendship Hospital, Beijing, China.
Background: Lung adenocarcinoma (LUAD), the most prevalent form of lung cancer. The transition from adenocarcinoma (AIS), and minimally invasive adenocarcinoma (MIA) to invasive adenocarcinoma (IAC) is not fully understood. Intratumoral microbiota may play a role in LUAD progression, but comprehensive stage-wise analysis is lacking.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!